Oct 7 (Reuters) - AstraZeneca said on Monday it would pay up to $1.9 billion to CSPC Pharmaceutical Group Ltd
in an exclusive license agreement to boost the Anglo-Swedish drugmaker's cardiovascular pipeline.
CSPC will get an upfront payment of $100 million to develop an early-stage, novel small molecule Lipoprotein (a) disruptor that could offer benefits to patients with dyslipidaemia, a disease characterised by elevated levels of so-called bad cholesterol, AstraZeneca said.
(Reporting by Yadarisa Shabong in Bengaluru)
((Yadarisa.Shabong@thomsonreuters.com; +91 9742735150;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.